[Community-based MRSA. A new challenge for dermatology].
Treatment options for infections with MRSA are extremely limited because of resistance to all beta-lactam antibiotics and primarily because of the fast acquisition of further antibiotic resistance. During the past six years MRSA possessing the genomic determinant of an additional virulence factor emerged. This virulence factor, Panton-Valentine-Leukocidin, seems to be responsible for deep skin infections as well as necrotizing pneumonia. In order to avoid a continuous spread of MRSA, consequent prevention measures both in dermatological practices and for colonized patients in their general environment are essential.
Bereich Wernigerode, Robert-Koch-Institut. wittew@rki.de
W
W
Witte
M
M
Wiese-Posselt
U
U
Jappe
D002353:Carrier State / Q000453:epidemiology / Q000382:microbiology; D017714:Community-Acquired Infections / Q000453:epidemiology* / Q000517:prevention & control* / Q000628:therapy; D003880:Dermatology / Q000379:methods* / Q000639:trends*; D005858:Germany / Q000453:epidemiology; D006801:Humans; D016106:Methicillin Resistance; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D015995:Prevalence; D013207:Staphylococcal Skin Infections / Q000453:epidemiology* / Q000517:prevention & control* / Q000628:therapy